Vertex Pharmaceuticals Incorporated
VRTX · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 8.93B | 7.85B | 4.31B | 3.32B | 12.97 |
| 2023 FY | 9.87B | 8.61B | 3.83B | 3.62B | 14.05 |
| 2024 FY | 11.02B | 9.49B | -232.90M | -535.60M | -2.08 |
| 2025 FY | 12.07B | 10.27B | 4.76B | 3.95B | 15.46 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 18.15B | 4.24B | 10.50B | 899.70M | 13.91B |
| 2023 FY | 22.73B | 5.15B | 10.37B | 808.40M | 17.58B |
| 2024 FY | 22.53B | 6.12B | 4.57B | 1.75B | 16.41B |
| 2025 FY | 26.14B | 7.48B | 5.09B | 3.88B | 18.67B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 4.13B | -204.70M | 3.93B | — | 3.71B |
| 2023 FY | 3.54B | -258.40M | 3.28B | — | -139.70M |
| 2024 FY | -492.60M | -297.70M | -790.30M | — | -5.80B |
| 2025 FY | 3.63B | -437.60M | 3.19B | — | 515.60M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 73.96B | 64.35B | — | — | — |
| 2023 FY | 104.86B | 95.29B | — | — | — |
| 2024 FY | 103.70B | 100.88B | — | — | — |
| 2025 FY | 115.92B | 114.72B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 2.96B | 2.56B | 1.15B | 1.03B | 4.02 |
| 2025 Q3 | 3.08B | 2.66B | 1.19B | 1.08B | 4.24 |
| 2025 Q4 | 3.23B | 2.76B | 1.30B | 1.19B | 4.69 |
| 2026 Q1 | 2.99B | 2.59B | 1.14B | 1.03B | 4.06 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 24.04B | 6.86B | 4.97B | 1.53B | 17.18B |
| 2025 Q3 | 24.86B | 7.54B | 4.94B | 1.83B | 17.32B |
| 2025 Q4 | 26.14B | 7.48B | 5.09B | 3.88B | 18.67B |
| 2026 Q1 | 26.48B | 7.12B | 5.49B | 1.99B | 19.36B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 1.07B | -145.70M | 927.40M | — | 296.60M |
| 2025 Q3 | 1.24B | -101.80M | 1.14B | — | -34.20M |
| 2025 Q4 | 498.00M | -149.40M | 348.60M | — | 140.00M |
| 2026 Q1 | 1.43B | -133.40M | 1.29B | — | 417.10M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 114.28B | 110.84B | — | — | — |
| 2025 Q3 | 100.10B | 97.00B | — | — | — |
| 2025 Q4 | 115.11B | 113.90B | — | — | — |
| 2026 Q1 | 113.47B | 109.96B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |